Literature DB >> 22856365

The effect of the neurogranin schizophrenia risk variant rs12807809 on brain structure and function.

Emma J Rose1, Derek W Morris, Ciara Fahey, Ian H Robertson, Ciara Greene, John O'Doherty, Fiona N Newell, Hugh Garavan, Jane McGrath, Arun Bokde, Daniela Tropea, Michael Gill, Aiden P Corvin, Gary Donohoe.   

Abstract

A single nucleotide polymorphism rs12807809 located upstream of the neurogranin (NRGN) gene has been identified as a risk variant for schizophrenia in recent genome-wide association studies. To date, there has been little investigation of the endophenotypic consequences of this variant, and our own investigations have suggested that the effects of this gene are not apparent at the level of cognitive function in patients or controls. Because the impact of risk variants may be more apparent at the level of brain, the aim of this investigation was to delineate whether NRGN genotype predicted variability in brain structure and/or function. Healthy individuals participated in structural (N = 140) and/or functional (N = 36) magnetic resonance imaging (s/fMRI). Voxel-based morphometry was used to compare gray and white matter volumes between carriers of the non-risk C allele (i.e., CC/CT) and those who were homozygous for the risk T allele. Functional imaging data were acquired during the performance of a spatial working memory task, and were also analyzed with respect to the difference between C carriers and T homozygotes. There was no effect of the NRGN variant rs12807809 on behavioral performance or brain structure. However, there was a main effect of genotype on brain activity during performance of the working memory task, such that while C carriers exhibited a load-independent decrease in left superior frontal gyrus/BA10, TT individuals failed to show a similar decrease in activity. The failure to disengage this ventromedial prefrontal region, despite preserved performance, may be indicative of a reduction in processing efficiency in healthy TT carriers. Although it remains to be established whether this holds true in larger samples and in patient cohorts, if valid, this suggests a potential mechanism by which NRGN variability might contribute to schizophrenia risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22856365     DOI: 10.1017/thg.2012.7

Source DB:  PubMed          Journal:  Twin Res Hum Genet        ISSN: 1832-4274            Impact factor:   1.587


  12 in total

Review 1.  On the other hand: including left-handers in cognitive neuroscience and neurogenetics.

Authors:  Roel M Willems; Lise Van der Haegen; Simon E Fisher; Clyde Francks
Journal:  Nat Rev Neurosci       Date:  2014-02-12       Impact factor: 34.870

2.  Neurogranin regulates sensorimotor gating through cortico-striatal circuitry.

Authors:  John M Sullivan; Caleb A Grant; Ashlie N Reker; Lailun Nahar; Nicholas E Goeders; Hyung W Nam
Journal:  Neuropharmacology       Date:  2019-03-19       Impact factor: 5.250

3.  Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas.

Authors:  Ryan P Lange; Allen Everett; Pratima Dulloor; Frederick K Korley; Chetan Bettegowda; Cherie Blair; Stuart A Grossman; Matthias Holdhoff
Journal:  Cancer Invest       Date:  2014-07-14       Impact factor: 2.176

Review 4.  Genetic underpinnings of white matter 'connectivity': heritability, risk, and heterogeneity in schizophrenia.

Authors:  Aristotle N Voineskos
Journal:  Schizophr Res       Date:  2014-06-02       Impact factor: 4.939

5.  Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.

Authors:  Donna Cosgrove; Omar Mothersill; Kimberley Kendall; Bettina Konte; Denise Harold; Ina Giegling; Annette Hartmann; Alex Richards; Kiran Mantripragada; Michael J Owen; Michael C O'Donovan; Michael Gill; Dan Rujescu; James Walters; Aiden Corvin; Derek W Morris; Gary Donohoe
Journal:  Neuropsychopharmacology       Date:  2017-06-13       Impact factor: 7.853

Review 6.  Imaging genetics and psychiatric disorders.

Authors:  R Hashimoto; K Ohi; H Yamamori; Y Yasuda; M Fujimoto; S Umeda-Yano; Y Watanabe; M Fukunaga; M Takeda
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

7.  Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia.

Authors:  Jamie Yu Jin Thong; Anqi Qiu; Min Yi Sum; Carissa Nadia Kuswanto; Ta Ahn Tuan; Gary Donohoe; Yih Yian Sitoh; Kang Sim
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

8.  MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls.

Authors:  D Cosgrove; D Harold; O Mothersill; R Anney; M J Hill; N J Bray; G Blokland; T Petryshen; A Richards; K Mantripragada; M Owen; M C O'Donovan; M Gill; A Corvin; D W Morris; G Donohoe
Journal:  Transl Psychiatry       Date:  2017-01-24       Impact factor: 6.222

9.  The impact of genome-wide supported schizophrenia risk variants in the neurogranin gene on brain structure and function.

Authors:  Esther Walton; Daniel Geisler; Johanna Hass; Jingyu Liu; Jessica Turner; Anastasia Yendiki; Michael N Smolka; Beng-Choon Ho; Dara S Manoach; Randy L Gollub; Veit Roessner; Vince D Calhoun; Stefan Ehrlich
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

10.  Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT).

Authors:  T Lencz; E Knowles; G Davies; S Guha; D C Liewald; J M Starr; S Djurovic; I Melle; K Sundet; A Christoforou; I Reinvang; S Mukherjee; Pamela DeRosse; A Lundervold; V M Steen; M John; T Espeseth; K Räikkönen; E Widen; A Palotie; J G Eriksson; I Giegling; B Konte; M Ikeda; P Roussos; S Giakoumaki; K E Burdick; A Payton; W Ollier; M Horan; G Donohoe; D Morris; A Corvin; M Gill; N Pendleton; N Iwata; A Darvasi; P Bitsios; D Rujescu; J Lahti; S L Hellard; M C Keller; O A Andreassen; I J Deary; D C Glahn; A K Malhotra
Journal:  Mol Psychiatry       Date:  2013-12-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.